These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23676495)

  • 1. Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.
    Gonzales JC; Gordts PL; Foley EM; Esko JD
    J Clin Invest; 2013 Jun; 123(6):2742-51. PubMed ID: 23676495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice.
    Stanford KI; Bishop JR; Foley EM; Gonzales JC; Niesman IR; Witztum JL; Esko JD
    J Clin Invest; 2009 Nov; 119(11):3236-45. PubMed ID: 19805913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triglyceride-rich lipoprotein binding and uptake by heparan sulfate proteoglycan receptors in a CRISPR/Cas9 library of Hep3B mutants.
    Anower-E-Khuda F; Singh G; Deng Y; Gordts PLSM; Esko JD
    Glycobiology; 2019 Jul; 29(8):582-592. PubMed ID: 31094413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase.
    Merkel M; Loeffler B; Kluger M; Fabig N; Geppert G; Pennacchio LA; Laatsch A; Heeren J
    J Biol Chem; 2005 Jun; 280(22):21553-60. PubMed ID: 15774484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans.
    Ji ZS; Sanan DA; Mahley RW
    J Lipid Res; 1995 Mar; 36(3):583-92. PubMed ID: 7539827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
    Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
    J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
    Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
    J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice.
    Foley EM; Gordts PLSM; Stanford KI; Gonzales JC; Lawrence R; Stoddard N; Esko JD
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2065-74. PubMed ID: 23846497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis.
    Schaap FG; Rensen PC; Voshol PJ; Vrins C; van der Vliet HN; Chamuleau RA; Havekes LM; Groen AK; van Dijk KW
    J Biol Chem; 2004 Jul; 279(27):27941-7. PubMed ID: 15090553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apolipoprotein C.
    van Barlingen HH; de Jong H; Erkelens DW; de Bruin TW
    J Lipid Res; 1996 Apr; 37(4):754-63. PubMed ID: 8732775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members.
    MacArthur JM; Bishop JR; Stanford KI; Wang L; Bensadoun A; Witztum JL; Esko JD
    J Clin Invest; 2007 Jan; 117(1):153-64. PubMed ID: 17200715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-dependent diabetes mellitus in mice does not alter liver heparan sulfate.
    Bishop JR; Foley E; Lawrence R; Esko JD
    J Biol Chem; 2010 May; 285(19):14658-62. PubMed ID: 20236939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.
    Ji ZS; Fazio S; Mahley RW
    J Biol Chem; 1994 May; 269(18):13421-8. PubMed ID: 8175773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells.
    Ji ZS; Brecht WJ; Miranda RD; Hussain MM; Innerarity TL; Mahley RW
    J Biol Chem; 1993 May; 268(14):10160-7. PubMed ID: 7683668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparan sulfate proteoglycans participate in hepatic lipaseand apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins.
    Ji ZS; Dichek HL; Miranda RD; Mahley RW
    J Biol Chem; 1997 Dec; 272(50):31285-92. PubMed ID: 9395455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E.
    de Silva HV; Lauer SJ; Wang J; Simonet WS; Weisgraber KH; Mahley RW; Taylor JM
    J Biol Chem; 1994 Jan; 269(3):2324-35. PubMed ID: 8294490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants.
    Grosskopf I; Baroukh N; Lee SJ; Kamari Y; Harats D; Rubin EM; Pennacchio LA; Cooper AD
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2573-9. PubMed ID: 16166565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors.
    Jiang J; Wu X; Tang H; Luo G
    PLoS One; 2013; 8(7):e67982. PubMed ID: 23844141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver.
    Mensenkamp AR; Jong MC; van Goor H; van Luyn MJ; Bloks V; Havinga R; Voshol PJ; Hofker MH; van Dijk KW; Havekes LM; Kuipers F
    J Biol Chem; 1999 Dec; 274(50):35711-8. PubMed ID: 10585451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice.
    Ebara T; Conde K; Kako Y; Liu Y; Xu Y; Ramakrishnan R; Goldberg IJ; Shachter NS
    J Clin Invest; 2000 Jun; 105(12):1807-18. PubMed ID: 10862796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.